Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 Bristol-Myers Squibb Co at UBS Global Healthcare Conference Transcript
May 21, 2019 / 06:30PM GMT
Release Date Price:
$46.31
(-0.65%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Good afternoon. My name is Navin Jacob. I'm the senior analyst covering pharmaceuticals and midcap biotech, UBS. Our next session is with Bristol-Myers Squibb. I'm happy to have with us Chairman and CEO, Giovanni Caforio. Giovanni, thank you for joining us today.
Giovanni Caforio
Bristol-Myers Squibb Company - Chairman of the Board & CEO
Thank you, Navin. Thank you. Good afternoon, everyone. Thanks for having me.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Giovanni, you're -- you have -- you're wearing many hats. You're Chairman and CEO of Bristol-Myers, going through a big deal. You're also a Chairman Elect of the Pharma Trade Group. Wondering given all the discussion around pharma pricing, IPI is coming out maybe over the next few weeks. We had
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot